Multiple Myeloma | Specialty

Carfilzomib Doubles PFS Over Bortezomib in Phase III Multiple Myeloma Trial

March 2nd 2015

Carfilzomib doubled progression-free survival versus bortezomib in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

FDA Approvals, Breakthrough Designations, Priority Reviews, and More

February 27th 2015

FDA Approves Panobinostat for Multiple Myeloma

February 23rd 2015

The FDA has approved panobinostat in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma, based on findings from the PANORAMA-1 trial.

Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More

February 20th 2015

Treatment Triplets Offer New Strategies in Relapsed Multiple Myeloma

February 20th 2015

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

Dr. Sundar Jagannath Discusses Approval of Lenalidomide in Multiple Myeloma

February 20th 2015

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

FDA Approves Frontline Revlimid for Multiple Myeloma

February 18th 2015

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

First Oral Proteasome Inhibitor Meets PFS Endpoint in Phase III Myeloma Trial

February 11th 2015

The proteasome inhibitor ixazomib met its primary endpoint of improving progression-free survival at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.

Experts Discuss New Diagnostic and Management Approaches in Multiple Myeloma

February 11th 2015

With the advent of safer and more effective treatments, early diagnosis of multiple myeloma (MM) has become an important goal.

Dr. Gertz on Expanding Treatment Options for Myeloma

February 6th 2015

Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.

Full Approval Sought for Carfilzomib in Multiple Myeloma

January 29th 2015

A supplemental New Drug Application has been submitted to the FDA for the full regulatory approval of carfilzomib as a treatment for patients with relapsed multiple myeloma.

Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients

January 20th 2015

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Pomalidomide Shows Benefits in Trials Testing New Combinations

January 20th 2015

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

Multiple Myeloma Advances: Noted Hematologist Envisions Big Changes in Treatment Paradigms

January 20th 2015

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.

Monoclonal Antibodies in Multiple Myeloma

January 12th 2015

Ixazomib and Elotuzumab in Multiple Myeloma

January 12th 2015

Pomalidomide and HDAC Inhibitors in Multiple Myeloma

January 12th 2015

Carfilzomib Combination in Relapsed Multiple Myeloma

January 12th 2015

Treatment of Elderly Patients With Multiple Myeloma

January 12th 2015

Transplant and Maintenance Therapy in Multiple Myeloma

January 12th 2015